Last reviewed · How we verify
RC1416
At a glance
| Generic name | RC1416 |
|---|---|
| Sponsor | Nanjing RegeneCore Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Trial of RC1416 Injection in Asthma (PHASE2)
- Phase II Study of RC1416 Injection in COPD (PHASE2)
- A Phase Ib Study of RC1416 Injection (PHASE1)
- A Phase I Study of RC1416 Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC1416 CI brief — competitive landscape report
- RC1416 updates RSS · CI watch RSS
- Nanjing RegeneCore Biotech Co., Ltd. portfolio CI